Hormone Therapy

Type 2 diabetes incidence rates do not differ between transgender adults after starting hormone therapy and cisgender adults, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.

A cohort of postmenopausal women from Finland had a bone mineral density decrease of about 10% during a follow-up period of 25 years, according to findings published in the Journal of Bone and Mineral Research.

Transgender people prescribed gender-affirming hormone therapy were no more likely to develop type 2 diabetes compared with cisgender adults, according to an analysis of electronic health records data.

New data showed that hormone therapy during menopause did not increase the risk for CVD or type 2 diabetes among middle-aged postmenopausal women. A report on the findings was the top story in endocrinology last week.

Menopausal hormone therapy does not affect risks for cardiovascular disease or type 2 diabetes, according to findings from a study of middle-aged postmenopausal women in South Korea published in Menopause.

New data presented at the European Society for Paediatric Endocrinology virtual meeting revealed that exposure to bisphenols, phthalates and perfluoroalkyl substances can increase the risk for obesity.

Menopausal hormone therapy is safe and effective for many women experiencing bothersome symptoms like hot flashes, but treatment should be individualized for people with certain risk factors, according to a speaker.

Healio and Cardiology Today have curated a list of the most-read cardiology news of August 2021.

Transgender women with HIV who received gender-affirming hormone therapy experienced significantly higher rates of sustained viral suppression, according to a study published in Open Forum Infectious Diseases.

Hormone therapy with exogenous estrogen, with and without progesterone, may increase the risk for asthma in women, according to new research published in Chest.